title: [Improvement of insulin sensitivity associated with the prolonged use of Acipimox in ++a morbid obese patient].
abstract: Insulin sensitivity was estimated in a morbidity obese, insulin-resistant, glucose-intolerant patient before and after 4 weeks of treatment with Acipimox (250 mg t.i.d), an orally-administered, long-acting antilypolitic drug. The ensuing fall in circulating levels of fasting free fatty acids was associated with a clear amelioration of insulin resistance, as assessed by a minimal model analysis of a frequently sampled intravenous glucose tolerance test as well as by an oral glucose tolerance test. Similarly, this treatment brought about a reappearance of GH response to oral stimulation with clonidine. The evidence showing Acipimox-induced amelioration of insulin resistance in this patient without diet, exercise or weight loss should encourage exploring the potential utility of this drug in this type of patients.
authors.affiliation: Sección Endocrinología, Facultad de Medicina (Campus Norte), Universidad de Chile, Hospital José, Joaquín Aguirre.
authors.forename: M L
authors.initials: ML
authors.lastname: Zura
authors.forename: P
authors.initials: P
authors.lastname: Contreras
authors.forename: C
authors.initials: C
authors.lastname: Aguirre
authors.forename: V
authors.initials: V
authors.lastname: Araya
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D009767:Obesity, Morbid / Q000097:blood / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D000960:Hypolipidemic Agents; D007328:Insulin; D011719:Pyrazines; C027696:acipimox
vernacular_title: Mejoría de la insulinosensibilidad asociada al uso prolongado de Acipimox en un obeso mórbido.